Zydus receives final approval from the USFDA for Cisatracurium Besylate Injection USP

Zydus receives final approval from the USFDA for Cisatracurium Besylate Injection USP

Zydus Cadila has received the final approval from the USFDA to market Cisatracurium Besylate Injection USP 10 mg (base)/5 mL (2 mg/mL) and 200 mg (base)/20 mL (10 mg/mL) Single-Dose Vials (Preservative-free) (US RLD- Nimbex). This medication is used to relax the muscles. It works by blocking the signals between one’s nerves and one’s muscles. This medicine is given before general anaesthesia in preparing for surgery. It will be manufactured at Liva Pharmaceuticals Limited, a wholly-owned subsidiary company of Cadila Healthcare Limited. The group now has 275 approvals and has so far filed over 360 ANDAs since the commencement of the filing process in FY 2003-04.

Cadila Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs over 24,000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020.